RAD-x continues German expansion - Gilde Healthcare

RAD-x continues German expansion

April 17, 2018

Utrecht, The Netherlands – Gilde Healthcare portfolio company RAD-x, the pan-European operator in diagnostic imaging, has announced that it has acquired Teleradiologisches Zentrum Koblenz (TelradKo). TelradKo provides teleradiology services to hospitals and hospital-based imaging centres in Germany. The combination with RAD-x enables TelradKo to accelerate its expansion and continue investing in the latest technology to establish itself as the leading provider of teleradiology services to small and medium sized hospitals.

 

About RAD-x

RAD-x is a fast-growing pan-European operator of diagnostic imaging centres, based on a network of local and regional centres. The network currently has a staff of over 350 healthcare professionals working in diagnostic imaging centres and hospitals. RAD-x’s growth model is based on the integration in its network of existing leading local and regional medical imaging centres and offering their radiologists to become shareholders of RAD-x. For more information, visit the company’s website at www.RAD-x.eu

About TelradKo

TelradKo is a provider of teleradiology services to hospitals and hospital-based imaging centres in Germany founded in 2014. For more information, visit the company’s website at www.telradko.de

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Benelux and Dach-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. Gilde Healthcare has raised €800 million ($1 billion) for its specialized funds. For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare company SpliceBio secures $135 Million financing to advance SB-007 in Stargardt disease and expand pipeline

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as Gilde Healthcare and other existing investors  Proceeds will support clinical development of lead program SB-007...
June 11, 2025

Gilde Healthcare participates in $75 Million Series D round of SpyGlass Pharma to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients

SpyGlass Pharma, a privately-held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide multiple years of medical therapy, addressing the need for long-term...
June 3, 2025

Gilde Healthcare company Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield

Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. ReActiv8...
April 28, 2025